Table I.

mIL-17R:Fc prolongs MHC-mismatched nonvascularized heart allograft survivala

Treatment, μg/day (timing)Graft Survival Time (days)Mean Survival Time (days)Median Survival Time (days)
huIgG13, 13, 13, 1513.5 ± 0.513
100 (days 0–2)
mIL-17R:Fc20, 20, 20, 2020b20
100 (days 0–2)
Rat IgG11, 14, 14, 1413.3 ± 0.814
300 (days 0–3)
mIL-17R:Fc19, 19, 19, 2119.5 ± 0.5c19
100 (days 0–3)
  • a The strain combination was BALB/c (H2d) to B6 (H2b).

  • b p < 0.001 when compared to control group given huIgG.

  • c p < 0.003 when compared to control group given rat IgG.